secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001437749-26-003808
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M
-----------------------------------------------------------------------

- Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.
- Net loss $0.8M vs net income $0.1M; diluted EPS $(0.03) vs $0.00.
- Six-month revenue $24.0M vs $26.2M; operating loss $0.7M vs income $0.7M.
- Two largest contract manufacturing customers accounted for ~89% of total revenue.
- Selling and administrative expenses decreased slightly to $0.9M from $1.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926003808/0001437749-26-003808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926003808/inbp20260205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-003808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer